Home › Colorectal Cancer › NCT07649057

A Study of a Urine Test to Detect Colorectal Cancer

Determining the Success of a Urine Metabolite Point-of-care Colorectal Cancer Early Diagnosis Test in Africa

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patient presents with one of the following:

  * Patients with symptoms of CRC (such as rectal bleeding for a week) -OR-
  * Patients who present for a screening colonoscopy -OR-
  * Has received one of the following within 3 weeks of the planned urine collection

    * Patients with a pathologic diagnosis of CRC either by colonoscopy or resection specimens -OR-
    * Patients with colonoscopy demonstrating adenomatous polyps -OR-
    * Patients with colonoscopy demonstrating no colon or premalignant or malignant pathology
* Age ≥ 18
* Willingness to participate in the study

About the study

The purpose of this study is to find out whether a urine test can detect colorectal cancer (CRC) and precancerous polyps in participants living in Ghana, Tanzania, and South Africa.

What is being tested

• 3-metabolite biosensor (diagnostic test)

Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 210 · Started: Jun 11, 2026

Contact the study team

• Peter Kingham, MD · Phone: 212-639-5260
• Alexia Iasonos, PhD · Phone: 646-227-3557

Official record on ClinicalTrials.gov — NCT07649057

Locations in the U.S.

Conditions

• Colorectal Cancer
• Gastrointestinal Bleeding

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.